1. Home
  2. HOWL vs GLU Comparison

HOWL vs GLU Comparison

Compare HOWL & GLU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HOWL
  • GLU
  • Stock Information
  • Founded
  • HOWL 2017
  • GLU 2004
  • Country
  • HOWL United States
  • GLU United States
  • Employees
  • HOWL N/A
  • GLU N/A
  • Industry
  • HOWL Biotechnology: Pharmaceutical Preparations
  • GLU Finance/Investors Services
  • Sector
  • HOWL Health Care
  • GLU Finance
  • Exchange
  • HOWL Nasdaq
  • GLU Nasdaq
  • Market Cap
  • HOWL 87.4M
  • GLU 92.2M
  • IPO Year
  • HOWL 2021
  • GLU N/A
  • Fundamental
  • Price
  • HOWL $1.49
  • GLU $15.87
  • Analyst Decision
  • HOWL Strong Buy
  • GLU
  • Analyst Count
  • HOWL 2
  • GLU 0
  • Target Price
  • HOWL $9.50
  • GLU N/A
  • AVG Volume (30 Days)
  • HOWL 260.9K
  • GLU 12.4K
  • Earning Date
  • HOWL 03-06-2025
  • GLU 01-01-0001
  • Dividend Yield
  • HOWL N/A
  • GLU 8.60%
  • EPS Growth
  • HOWL N/A
  • GLU N/A
  • EPS
  • HOWL N/A
  • GLU 0.62
  • Revenue
  • HOWL $3,386,000.00
  • GLU N/A
  • Revenue This Year
  • HOWL N/A
  • GLU N/A
  • Revenue Next Year
  • HOWL $34.17
  • GLU N/A
  • P/E Ratio
  • HOWL N/A
  • GLU $22.50
  • Revenue Growth
  • HOWL N/A
  • GLU N/A
  • 52 Week Low
  • HOWL $1.26
  • GLU $11.61
  • 52 Week High
  • HOWL $8.19
  • GLU $15.40
  • Technical
  • Relative Strength Index (RSI)
  • HOWL 54.09
  • GLU 59.92
  • Support Level
  • HOWL $1.28
  • GLU $15.46
  • Resistance Level
  • HOWL $1.60
  • GLU $15.87
  • Average True Range (ATR)
  • HOWL 0.10
  • GLU 0.30
  • MACD
  • HOWL 0.03
  • GLU 0.06
  • Stochastic Oscillator
  • HOWL 67.65
  • GLU 87.50

About HOWL Werewolf Therapeutics Inc.

Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.

About GLU Gabelli Global Utility of Beneficial Ownership

Gabelli Global Utility & Income Trust is a non-diversified, closed-end management investment company. The Fund's objective is to seek a consistent level of after-tax total return. It predominantly invests in stocks of companies involved to a substantial extent in providing products, services, or equipment for the generation or distribution of electricity, gas, or water and infrastructure operations, and in equity securities including preferred securities of companies in other industries, in each case in such securities that are expected to pay periodic dividends.

Share on Social Networks: